A Phase 1 interventional study of Daridorexant in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-12.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to measure daridorexant in breast milk of healthy lactating women
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daridorexant 50 mg will be administered once in the morning of Day 1.
Drug: Daridorexant
Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
Milk pharmacokinetic endpoints: Amount of daridorexant excreted (mg)
Cumulative amount excreted in breast milk over the collection time
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
Milk pharmacokinetic endpoints: Fraction (percentage) of dose excreted in breast milk
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
Milk pharmacokinetic endpoints: Relative infant daridorexant dose (percentage)
Percentage of dose that would be consumed by the infant, adjusted to maternal weight and infant weight on Day -1
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
Plasma pharmacokinetic endpoints: Cmax
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
Plasma pharmacokinetic endpoints: Tmax
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
Plasma pharmacokinetic endpoints: AUC0-inf
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
Plasma pharmacokinetic endpoints: T1/2
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
Treatment-emergent (S)AEs
Time frame: Up to end of study (EOS; total duration: up to 46 days)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2023 to primary completion in Apr 2023, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Idorsia Pharmaceuticals Ltd. →